Risk stratification in the hormonal treatment of patients with prostate cancer
- PMID:21789114
- PMCID: PMC3125993
- DOI: 10.1177/1758834009340164
Risk stratification in the hormonal treatment of patients with prostate cancer
Abstract
Prostate cancer (PCa) is the most common type of cancer found in American men, other than skin cancer. The American Cancer Society estimates that there will be 186,320 new cases of prostate cancer in the United States in 2008. About 28,660 men will die of this disease this year and PCa remains the second-leading cause of cancer death in men. One in six men will get PCa during his lifetime and one in 35 will die of the disease. Today, more than 2 million men in the United States who have had PCa are still alive. The death rate for PCa continues to decline, chiefly due to early detection and treatment, and improved salvage therapy such as hormone therapy (HT). HT continues to be a mainstay for primary-recurrent PCa and locally-advanced PCa. However, HT is associated with many undesirable side effects including sexual dysfunction, osteoporosis and hot flashes, all of which can lead to decreased quality of life (QOL). These risks are seen in both long- and short-term HT regimens. Additionally, research in recent years has revealed trends related to clinico pathological variables and their predictive ability in HT outcomes. Awareness of the potential adverse effects, the risks associated with HT and the prognostic ability of clinical and pathological variables is important in determining optimal therapy for individual patients. A rigorous evaluation of the current scientific literature associated with HT was conducted with the goal of identifying the most favorable balance of benefits and risks associated with HT.
Keywords: hormonal therapy; prostate cancer; quality of life; recurrence; risk factors; survival; toxicity.
Similar articles
- Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.Moris L, Cumberbatch MG, Van den Broeck T, Gandaglia G, Fossati N, Kelly B, Pal R, Briers E, Cornford P, De Santis M, Fanti S, Gillessen S, Grummet JP, Henry AM, Lam TBL, Lardas M, Liew M, Mason MD, Omar MI, Rouvière O, Schoots IG, Tilki D, van den Bergh RCN, van Der Kwast TH, van Der Poel HG, Willemse PM, Yuan CY, Konety B, Dorff T, Jain S, Mottet N, Wiegel T.Moris L, et al.Eur Urol. 2020 May;77(5):614-627. doi: 10.1016/j.eururo.2020.01.033. Epub 2020 Mar 4.Eur Urol. 2020.PMID:32146018
- Overview of resistance to systemic therapy in patients with breast cancer.Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.Gonzalez-Angulo AM, et al.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.Adv Exp Med Biol. 2007.PMID:17993229Review.
- Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N.van den Bergh RC, et al.Eur Urol. 2016 May;69(5):802-20. doi: 10.1016/j.eururo.2015.11.023. Epub 2015 Dec 12.Eur Urol. 2016.PMID:26691493Review.
- A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY.Spratt DE, et al.Eur Urol. 2018 Feb;73(2):156-165. doi: 10.1016/j.eururo.2017.06.027. Epub 2017 Jul 14.Eur Urol. 2018.PMID:28716370
- Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.Gomella LG.Gomella LG.BJU Int. 2007 Jan;99 Suppl 1:25-9; discussion 30. doi: 10.1111/j.1464-410X.2007.06598.x.BJU Int. 2007.PMID:17229166Review.
Cited by
- Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data.Cheung S, Hamuro Y, Mahlich J, Nakayama M, Tsubota A.Cheung S, et al.PLoS One. 2018 Apr 25;13(4):e0195789. doi: 10.1371/journal.pone.0195789. eCollection 2018.PLoS One. 2018.PMID:29694373Free PMC article.
References
- Akaza H., Homma Y., Usami M., Hirao Y., Tsushima T., Okada K., et al. (2006) Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10–year follow–up. BJU Int 98: 573–579 - PubMed
- Amling C.L., Blute M.L., Bergstralh E.J., Seay T.M., Slezak J., Zincke H. (2000) Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 164: 101–105 - PubMed
- Banez L.L., Blake G.W., Mcleod D.G., Crawford E.D., Moul J.W. (2009) Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase ii trials with a long-term follow-up. BJU Int [Epub ahead of print]. - PubMed
- Berruti A., Dogliotti L., Terrone C., Cerutti S., Isaia G., Tarabuzzi R., et al. (2002) Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167: 2361–2367; discussion 2367. - PubMed
LinkOut - more resources
Full Text Sources